Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted ... Read more
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 ... Read more
Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful ... Read more
Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API) ... Read more
Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important ... Read more
Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of ... Read more